Department of Medicine 1 – Gastroenterology, Pneumology and Endocrinology

Evaluation of multidisciplinary team decisions in neuroendocrine neoplasms: Impact of expert centres (2022) Zandee WT, Merola E, Poczkaj K, de Mestier L, Klümpen HJ, Geboes K, de Herder WW, Munir A Journal article Pig models for Duchenne muscular dystrophy – from disease mechanisms to validation of new diagnostic and therapeutic concepts (2022) Stirm M, Fonteyne LM, Shashikadze B, Stöckl JB, Kurome M, Keßler B, Zakhartchenko V, et al. Journal article, Review article The first virtual chromoendoscopy artificial intelligence system to detect endoscopic and histologic remission in Ulcerative Colitis (2022) Iacucci M, Cannatelli R, Parigi TL, Buda A, Labarile N, Nardone OM, Tontini GE, et al. Conference contribution A new simplified histology artificial intelligence system for accurate assessment of remission in Ulcerative Colitis (2022) Villanacci V, Parigi TL, Del Amor R, Esbri PM, Gui X, Bazarova A, Bhandari P, et al. Conference contribution A comparative efficacy and safety analysis of subcutaneous infliximab and vedolizumab in patients with Crohn's Disease and Ulcerative Colitis (2022) Peyrin-Biroulet L, Arkkila P, Armuzzi A, Atreya R, Danese S, Ferrante M, Guardiola J, et al. Conference contribution Normalisation of biomarkers and improvement in clinical outcomes in patients with Crohn's Disease treated with risankizumab in the phase 3 ADVANCE, MOTIVATE, and FORTIFY studies (2022) Atreya R, Feagan B, Shchukina O, Jairath V, Rieder F, Hisamatsu T, Siegmund B, et al. Conference contribution Real World Evidence on the comparative effectiveness of Ustekinumab vs anti-TNF in Crohn's disease with Propensity Score adjustment: maintenance phase results from the prospective observational RUN-CD study (2022) Bokemeyer B, Plachta-Danielzik S, Di Giuseppe R, Deppe H, Mohl W, Teich N, Hoffstadt M, et al. Conference contribution Efficacy of risankizumab rescue therapy in patients with moderately to severely active Crohn's Disease and inadequate response to risankizumab maintenance therapy (2022) Baert FJ, Atreya R, Kakuta Y, Long M, Roblin X, Neimark E, Song A, et al. Conference contribution Neutrophils prevent rectal bleeding in Ulcerative Colitis by peptidyl-arginine deiminase-4-dependent immunothrombosis (2022) Leppkes M, Lindemann A, Goesswein S, Paulus S, Roth D, Hartung A, Liebing E, et al. Conference contribution Comparative real-world effectiveness and persistence of vedolizumab versus anti-TNF therapy in biologic-naive patients with Crohn's Disease with Propensity Score adjustment: Maintenance phase results at week-52 from the prospective VEDOIBD study (2022) Di Giuseppe R, Plachta-Danielzik S, Bokemeyer B, Efken P, Mohl W, Hoffstadt M, Krause T, et al. Conference contribution